文献速递消化内镜消化道肿瘤与早癌

内镜医师结肠镜质量指标与粪便检测阳性后随访结肠镜结局的关联:新罕布什尔结肠镜登记处数据的回顾性横断面分析

Association of Endoscopist Colonoscopy Quality Measures With Follow-Up Colonoscopy Outcomes After Positive Stool Tests (Multitarget Stool DNA or Fecal Immunochemical Test): Retrospective Cross-Sectional Analysis of Data From the New Hampshire Colonoscopy Registry.
PubMed 文献 · Am J Gastroenterol · 2024-04-17

基于新罕布什尔结肠镜登记处数据,回顾性分析864例多靶点粪便DNA检测阳性与497例粪便免疫化学检测阳性患者,比较不同腺瘤检出率与临床显著锯齿状息肉检出率四分位内镜医师的结肠镜阴性率及息肉检出情况。结果显示高检出率医师的结肠镜阴性率显著更低,第四四分位腺瘤检出率医师在粪便检测阳性后任何腺瘤检出率为63.3%(FIT+)与62.8%(mt-sDNA+);第四四分位临床显著锯齿状息肉检出率医师在mt-sDNA+后无蒂锯齿状病变检出率为29.2%,FIT+后为13.5%。作者提出mt-sDNA+或FIT+患者腺瘤检出率基准目标至少40%,mt-sDNA+患者无蒂锯齿状病变至少20%。

要点

  • 腺瘤检出率与临床显著锯齿状息肉检出率高的内镜医师,粪便检测阳性后结肠镜阴性率显著更低。
  • 第四四分位腺瘤检出率医师在FIT+与mt-sDNA+后任何腺瘤检出率分别为63.3%与62.8%。
  • 第四四分位临床显著锯齿状息肉检出率医师在mt-sDNA+与FIT+后无蒂锯齿状病变检出率分别为29.2%与13.5%。

核心结论

  • 粪便检测阳性后结肠镜阴性率在内镜医师腺瘤检出率与临床显著锯齿状息肉检出率低时显著更高。
  • 作者提出mt-sDNA+或FIT+患者腺瘤检出率基准目标至少40%,mt-sDNA+患者无蒂锯齿状病变至少20%。

研究设计与样本

  • 回顾性横断面分析,使用新罕布什尔结肠镜登记处数据。
  • 样本包括864例mt-sDNA+患者与497例FIT+患者。
  • 按内镜医师腺瘤检出率与临床显著锯齿状息肉检出率四分位比较结肠镜阴性率与特定息肉频率。

主要发现

  • 腺瘤检出率与临床显著锯齿状息肉检出率较高的内镜医师,粪便检测阳性后结肠镜阴性率显著更低,尤其在最高两个四分位。
  • 第四四分位腺瘤检出率医师在粪便检测阳性后任何腺瘤检出率为63.3%(FIT+)与62.8%(mt-sDNA+)。
  • 第四四分位临床显著锯齿状息肉检出率医师在mt-sDNA+后无蒂锯齿状病变检出率为29.2%,FIT+后为13.5%。

关键数值与推荐

  • 作者提出mt-sDNA+或FIT+患者腺瘤检出率基准目标至少40%。
  • 作者提出mt-sDNA+患者无蒂锯齿状病变基准目标至少20%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Negative colonoscopies following positive stool tests could result from stool test characteristics or from the quality of endoscopist performance. We used New Hampshire Colonoscopy Registry data to examine the association between endoscopist detection rates and polyp yield in colonoscopies performed for positive fecal immunochemical test (FIT) or multitarget stool DNA (mt-sDNA) test to evaluate the degree to which positive stool tests followed by negative colonoscopy ("false positives") vary with endoscopist quality. In addition, we investigated the frequency of significant polyps in the subgroup of highest quality colonoscopies following positive stool tests. METHODS: We compared the frequencies of negative colonoscopies and of specific polyps following positive stool tests across quartiles of endoscopist adenoma detection rate (ADR) and clinically significant serrated polyp detection rate (CSSDR). RESULTS: Our sample included 864 mt-sDNA+ and 497 FIT+ patients. We found a significantly lower frequency of negative colonoscopies following positive stool tests among endoscopists with higher ADR and CSSDR, particularly in the 2 highest quartiles. In addition, detection of any adenoma after a positive stool test for endoscopists in the fourth ADR quartile was 63.3% (FIT+) and 62.8% (mt-sDNA+). Among endoscopists in the fourth CSSDR quartile, sessile serrated lesions were found in 29.2% of examinations following a positive mt-sDNA and in 13.5% following FIT+ examinations. DISCUSSION: The frequency of negative colonoscopies after positive stool tests was significantly higher in examinations performed by endoscopists with low ADR and CSSDR. Our results also suggest a benchmark target of at least 40% for ADR in patients with mt-sDNA+ or FIT+ tests and 20% for sessile serrated lesions in mt-sDNA+ patients.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Butterly LF, Hisey WM, Robinson CM, et al. Association of Endoscopist Colonoscopy Quality Measures With Follow-Up Colonoscopy Outcomes After Positive Stool Tests (Multitarget Stool DNA or Fecal Immunochemical Test): Retrospective Cross-Sectional Analysis of Data From the New Hampshire Colonoscopy Registry. Am J Gastroenterol. 2024. PMID: 38629701. doi:10.14309/ajg.0000000000002817

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。